Progenics Pharmaceuticals (PGNX) in Focus: Stock Falls 5.5%

Zacks Equity Research

Progenics Pharmaceuticals, Inc. (PGNX) saw a big move last session, as the company’s shares fell by nearly 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for PGNX, as the stock is now down nearly 6% in the past one-month time frame. 

This slump shouldn’t be too much of a surprise to investors, as the company has seen 1 negative revision in the past few weeks and its current year earnings consensus has moved lower over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.

PGNX currently has a Zacks Rank #3 (Hold) while its Earnings ESP is zero.

Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP), Gilead Sciences Inc. (GILD) and Illumina Inc. (ILMN). All these stocks carry a Zacks Rank #1 (Strong Buy).   

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>




PROGENICS PHARMA INC (PGNX): Free Stock Analysis Report

ANI PHARMACEUTICALS INC (ANIP): Free Stock Analysis Report

GILEAD SCIENCES INC (GILD): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report


Zacks Investment Research